Lineage Cell Therapeutics Inc (LCTX)
Drugs • Health Care
July 30, 2026 Lineage Cell Therapeutics Set to Release Q2 2026 Financial Results and Business Update Lineage Cell Therapeutics is set to release its Q2 2026 financial results on August 6, 2026. The company, known for its allogeneic cell therapies, will discuss its performance and future strategies during a conference call, highlighting its promising pipeline aimed at serious medical conditions.
July 13, 2026 Lineage Cell Therapeutics Provides Key Update on COR1 Cell Therapy Program Lineage Cell Therapeutics has made significant advancements in its COR1 program, which focuses on developing allogeneic corneal endothelial cells to improve treatment for corneal diseases. The proprietary AlloSCOPE platform enhances production efficiency, aiming to meet the global demand for corneal transplants.
July 06, 2026 Lineage Cell Therapeutics to Showcase Innovations at B. Riley Securities Healthcare Summit Lineage Cell Therapeutics will showcase its innovative allogeneic cell therapies at the B. Riley Securities Healthcare Summit. CEO Brian M. Culley will discuss the company's advancements and product pipeline, emphasizing its commitment to improving patient outcomes.
May 05, 2026 Lineage Cell Therapeutics Set to Release Q1 2026 Financial Results and Business Update Lineage Cell Therapeutics is set to release its Q1 2026 financial results on May 12, 2026, followed by a conference call to discuss insights and strategies. The company's innovative allogeneic cell therapies are in various stages of development, attracting keen interest from investors and analysts.
April 13, 2026 Lineage Cell Therapeutics Forms Scientific Advisory Board to Propel Cell Therapy Innovations Lineage Cell Therapeutics has established a Scientific Advisory Board to guide its cell therapy pipeline, led by Dr. Joachim Fruebis. The company aims to advance innovative allogeneic therapies, leveraging its proprietary AlloSCOPE™ platform for scalable and effective treatments.
March 24, 2026 Lineage Cell Therapeutics Expands Pipeline with New Corneal Endothelial Disease Program Lineage Cell Therapeutics has launched its COR1 program to address corneal endothelial disease, a condition affecting millions. Utilizing its AlloSCOPE platform, the company aims to provide scalable and effective cell therapies, reducing reliance on donor corneas and improving patient outcomes.
March 05, 2026 Lineage Cell Therapeutics Inc. Reports 2025 Annual Results: A Year of Growth Amid Challenges Lineage Cell Therapeutics Inc. reported significant growth in its 2025 annual results, showcasing a revenue increase alongside challenges from geopolitical tensions. The company is focused on innovative cell therapies, with ongoing development of key programs like OpRegen and OPC1.
November 06, 2025 Lineage Cell Therapeutics Inc. Reports Q3 2025 Results: Navigating Challenges in Biotechnology Lineage Cell Therapeutics Inc. reported its Q3 2025 results, revealing a net loss of $29.78 million amid strategic investments in R&D. The company faces operational challenges due to geopolitical tensions but continues to advance its innovative cell therapies.
August 12, 2025 Lineage Cell Therapeutics Inc.: Q2 2025 Financial Report Analysis Lineage Cell Therapeutics Inc. reported a Q2 2025 net loss of $30.46 million, increasing operational expenses and facing challenges from regional conflicts. Despite financial pressures, the company is advancing its innovative cell therapies, including OpRegen and OPC1, while preparing for future funding needs.
May 14, 2025 Lineage Cell Therapeutics Set to Showcase Innovations at H.C. Wainwright BioConnect Investor Conference Lineage Cell Therapeutics will present at the H.C. Wainwright BioConnect Investor Conference, highlighting its advancements in allogeneic cell therapies. CEO Brian M. Culley will discuss the company's innovative pipeline, including therapies for retinal and spinal cord injuries. Investors can engage with management for deeper insights.
May 13, 2025 Lineage Cell Therapeutics Inc. Reports Q1 2025 Financial Results: A Mixed Bag of Progress and Challenges Lineage Cell Therapeutics reported a net loss of $4.13 million in Q1 2025, despite a revenue increase to $1.50 million. The company continues to advance its innovative therapies, including OpRegen® for AMD, while facing ongoing operational challenges and seeking additional funding.
May 13, 2025 Lineage Cell Therapeutics Reports Promising Q1 2025 Financial Results and Strategic Updates Lineage Cell Therapeutics reported strong Q1 2025 results with $1.5 million in revenue, highlighting advancements in OpRegen for AMD and the launch of the OPC1 study for spinal injuries. The company remains focused on strategic growth in cell therapies, positioning itself for future success.
May 12, 2025 Lineage Cell Therapeutics Unveils 36-Month Results of RG6501 (OpRegen) at Clinical Trials at the Summit 2025 Lineage Cell Therapeutics will present the 36-month results of RG6501 (OpRegen) for geographic atrophy at CTS 2025. This innovative therapy aims to rejuvenate retinal health, addressing a major cause of blindness and highlighting Lineage's commitment to regenerative medicine.
May 01, 2025 Lineage Cell Therapeutics to Unveil Q1 2025 Financial Results and Strategic Update Lineage Cell Therapeutics is set to report its Q1 2025 financial and operational results on May 13, 2025. The report will cover revenue figures and progress in their innovative therapies for neurological conditions. A conference call will follow to discuss the details.
April 22, 2025 Lineage Cell Therapeutics and Reeve Foundation Announce 3rd Annual Spinal Cord Injury Investor Symposium Lineage Cell Therapeutics and the Reeve Foundation are hosting the 3rd Annual Spinal Cord Injury Investor Symposium on June 27, 2025. This virtual event aims to unite stakeholders to discuss innovations and improve awareness in spinal cord injury research and treatment.
April 21, 2025 Lineage Cell Therapeutics to Showcase Innovations at Eyecelerator 2025 Lineage Cell Therapeutics will present at Eyecelerator 2025, highlighting their innovative cell therapies for eye care. CEO Brian M. Culley will participate in a panel discussing novel drug delivery approaches for glaucoma and retina, alongside industry leaders.
March 10, 2025 Lineage Cell Therapeutics Inc. Reports 2024 Annual Results: A Year of Resilience and Strategic Advancements Lineage Cell Therapeutics reported a revenue increase to $9.49 million in 2024, driven largely by collaboration revenues. Despite a net loss of $18.60 million, strategic advancements in their product pipeline and partnerships position the company for future growth.
March 10, 2025 Lineage Cell Therapeutics Reports Strong Progress in 2024 Financial Results and Business Developments Lineage Cell Therapeutics reported significant advancements in 2024, including the success of its OpRegen program and a robust financial position. The company is poised for growth in 2025 as it continues to innovate in cell therapies.
March 05, 2025 Lineage Cell Therapeutics Set to Reveal 2024 Financial Results on March 10, 2025 Lineage Cell Therapeutics is set to release its financial results for 2024 on March 10, 2025. The company specializes in allogeneic cell therapies for neurological conditions and will detail its pipeline and strategic direction during a conference call.
March 02, 2025 SWOT Analysis of Lineage Cell Therapeutics Inc in 2025 This SWOT analysis examines Lineage Cell Therapeutics Inc's strategic position in 2025, detailing its strengths in innovative therapies and partnerships, along with weaknesses and external threats it faces. The article outlines potential growth opportunities in the biotech landscape while emphasizing the importance of addressing existing challenges.
February 11, 2025 Lineage Cell Therapeutics Initiates Clinical Study of OPC1 for Spinal Cord Injury Lineage Cell Therapeutics has initiated the DOSED clinical study to assess the OPC1 therapy for spinal cord injuries. The study focuses on safety and efficacy using a novel delivery system, marking a significant step for chronic injury treatment.
November 14, 2024 Lineage Cell Therapeutics Inc. Reports Q3 2024: Progress Amidst Challenges Lineage Cell Therapeutics reported improved financial results for Q3 2024, including a reduced net loss and increased revenue. Despite challenges from geopolitical events, the company remains focused on growth through strategic collaborations.
August 08, 2024 Lineage Cell Therapeutics Inc. Reports Q2 2024 Financial Results Lineage Cell Therapeutics Inc. reported a revenue decline to $1.8 million for Q2 2024, with increased operating expenses and a net loss of $12.5 million. The company continues to focus on its innovative cell therapy pipeline while seeking additional funding to navigate financial challenges.
May 09, 2024 Lineage Cell Therapeutics Inc. Releases Q1 2024 Financial Results: A Challenging Start to the Year Lineage Cell Therapeutics Inc. reported a net loss of $6.54 million in Q1 2024, driven by increased R&D and operational expenses. The company remains committed to advancing its innovative cell therapies while navigating financial and geopolitical challenges.